- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01568489
Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis
September 21, 2015 updated by: HanAll BioPharma Co., Ltd.
A Randomized, Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of HL-009 Liposomal Gel in Adult Patients With Mild to Moderate Atopic Dermatitis
The objective of this phase 2 study is to evaluate the safety and efficacy of HL-009 Liposomal Gel in adult patients with mild to moderate atopic dermatitis (AD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with mild to moderate AD.
Following a 2-week screening period, subjects will be randomly assigned into one of four treatment arms.
Placebo or HL-009 study treatments will be administrated to subjects twice daily for 8 consecutive weeks.
After the randomization at Week 0 (Visit 2), subjects will visit their respective trial sites at Weeks 0.5, 1, 2, 4, 6, 8, and 10 (Visits 3, 4, 5, 6, 7, 8, and 9).
All study drugs will be in identical laminated tubes to preserve double-blinding of the study.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Arlington Heights, Illinois, United States, 60025
-
-
Minnesota
-
Fridley, Minnesota, United States, 55432
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
-
-
Ohio
-
South Euclid, Ohio, United States, 44118
-
-
Oregon
-
Portland, Oregon, United States, 97223
-
-
Texas
-
Austin, Texas, United States, 78759
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males or females aged 18 or older
- Clinical diagnosis of AD by a board certified/eligible dermatologist
- Subjects who have body surface area affected to at least 2% total body surface area (BSA)
- Subjects with IGA score 2 or 3 corresponding to mild to moderate AD at screening and baseline visits
- Subjects who can give written informed consent
Exclusion Criteria:
- Subjects who had topical treatment with corticosteroids within 2 weeks before screening
- Subjects who had systemic treatment with corticosteroids or ciclosporin and photopheresis treatment within 2 weeks before screening
- Subjects who had ultraviolet irradiation within 2 weeks before screening
- Subjects who participated in another drug trial within 4 weeks before screening
- Subjects who have an allergy to one of the excipients
- Female subjects who have a positive serum pregnancy test at screening, plan a pregnancy during study period, or are breast feeding
- Female subjects who don't meet one of the following criteria: Be surgically sterile,Post-menopausal for at least 12 months, or If sexually active, they should use oral contraceptives, double barrier contraception, intrauterine device, or other methods approved by the sponsor
- Subjects who have other topical treatment of the AD area
- Subjects who take any systemic anti-infective or antibiotic treatment
- Subjects who had eczema herpeticum
- Subjects who have any clinically significant presence of skin disease or pigmentation other than atopic dermatitis, or wide scar on atopic dermatitis area
- Subjects who have poorly-controlled chronic disease
- Subjects who have significant medical problems, including but not limited to uncontrolled hypertension and congestive heart failure
- Subjects who have clinically significant laboratory abnormalities at screening
- Subjects who have a marked prolongation of QT/QTc interval at screening
- Subjects who have a history of additional risk factors for TdP
- Subjects who use a medication that prolongs the QT/QTc interval
- Subjects who, in the opinion of the investigator, would be non-compliant with the visit schedule of study procedures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HL-009 Liposomal Gel (0.07%)
|
a semi-transparent red-color gel and is supplied as a laminated tube
|
EXPERIMENTAL: HL-009 Liposomal Gel (0.15%)
|
a semi-transparent red-color gel and is supplied as a laminated tube
|
EXPERIMENTAL: HL-009 Liposomal Gel (0.30%)
|
a semi-transparent red-color gel and is supplied as a laminated tube
|
PLACEBO_COMPARATOR: HL-009 Liposomal Gel (Placebo)
|
a semi-transparent red-color gel and is supplied as a laminated tube
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Score change from baseline on IGA at Week 8
Time Frame: Weeks 0, 1, 2, 4, 6, and 8
|
Weeks 0, 1, 2, 4, 6, and 8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of subjects who have a minimum of 2-point improvement in IGA score at Week 8
Time Frame: Weeks 0, 1, 2, 4, 6, and 8
|
Weeks 0, 1, 2, 4, 6, and 8
|
Score change from baseline on EASI at Week 8
Time Frame: Weeks 0, 1, 2, 4, 6, and 8
|
Weeks 0, 1, 2, 4, 6, and 8
|
Score change from baseline on VAS for pruritus at Week 8
Time Frame: Weeks 0, 1, 2, 4, 6, and 8
|
Weeks 0, 1, 2, 4, 6, and 8
|
Score change from baseline on DLQI at Week 8
Time Frame: Weeks 0, 1, 2, 4, 6, and 8
|
Weeks 0, 1, 2, 4, 6, and 8
|
Score change from baseline on SF-36 questionnaires at Week 8
Time Frame: Weeks 0, 4, and 8
|
Weeks 0, 4, and 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (ACTUAL)
August 1, 2013
Study Completion (ACTUAL)
August 1, 2013
Study Registration Dates
First Submitted
March 29, 2012
First Submitted That Met QC Criteria
March 30, 2012
First Posted (ESTIMATE)
April 2, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
September 23, 2015
Last Update Submitted That Met QC Criteria
September 21, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HL-009-ADP2-US-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild to Moderate Atopic Dermatitis
-
Wake Forest University Health SciencesActive, not recruiting
-
Bitop AGCompletedMild to Moderate Atopic DermatitisGermany
-
MEDA PHARMA SPA, a Viatris companyNot yet recruitingMild to Moderate Atopic Dermatitis
-
Creabilis SATerminated
-
HK inno.N CorporationNot yet recruiting
-
Greenpharma S.A.S.Complife Italia S.r.lCompletedMild to Moderate Atopic DermatitisItaly
-
BayerCompletedMild to Moderate Atopic DermatitisGermany
-
Sterna Biologicals GmbH & Co. KGCompletedMild to Moderate Atopic DermatitisGermany
-
Regeneron PharmaceuticalsSanofiCompletedModerate to Severe Atopic Hand and Foot DermatitisUnited States, Germany, Japan, Poland
-
medac GmbHNot yet recruitingModerate to Severe Atopic Dermatitis
Clinical Trials on HL-009 Liposomal Gel
-
Soroka University Medical CenterCompleted
-
Cyanotech CorporationUniversity of South FloridaCompleted
-
Taro Pharmaceuticals USACompleted
-
University of Colorado, DenverSociety for Pediatric DermatologyCompleted
-
National Cancer Institute (NCI)WithdrawnRecurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma
-
National Cancer Institute (NCI)RecruitingLymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditionsUnited States